← SynDRA
CILASTATIN
SynDRA canonical compound SYN0001762 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | DPEP1 |
|---|
| Mechanism of action | dehydropeptidase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- DPEP1 INHIBITOR
- Renal dipeptidase inhibitor
- dehydropeptidase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABL1
- GMNN
- HDAC6
- HRH3
- HTR1A
- HTR2B
- KCNH2
- MAOA
- MAPK1
- OPRM1
- PDE3A
- PDE4A
- PGR
- PTGS1
- SLC22A7
- SLC6A2
- SLC6A3
- SLC6A4
- TBXA2R
- GSK3B
- FGFR3
- ACHE
- F2
- ADORA1
- ADRA1A
- ADRA2A
- APEX1
- AR
- AURKA
- BRD4
- BRPF1
- CBX1
- CDK2
- CHRM1
- CHRM2
- CSNK1D
- DRD1
- DRD3
- ERG
- ESR1
Drug classes
- Dipeptidase Inhibitors
- Renal Dehydropeptidase Inhibitor
- Enzyme Inhibitors
- Protease Inhibitors
- Anti-Bacterial Agents
ATC classes
- OTHER BETA-LACTAM ANTIBACTERIALS
Cross-references
Synonyms
- IMIPENEM AND CILASTATIN
- PRIMAXIN
- Primaxin
- RECARBRIO
- Recarbrio
- cilastatin sodium
- cilastin
- cilastatin monosodium
- Cilastatine
- Cilastatina
- Cilastatinum
- Cilastatin Monosodium Salt
- Cilastatin acid
- Cilastatina [Spanish]
- Cilastatine [French]
- Cilastatinum [Latin]
- MK0791
- Cilastatin (INN)
- Cilastatin [INN:BAN]
- MK-791
- MK 791
- CHEBI:3697
- MK791
- RefChem:126129
- DTXCID3028213
- MFCD00867379
- CILASTATIN [INN]
- MK 0791
- C16H26N2O5S
- Cilastin
- NCGC00181346-01
- EINECS 279-875-8
- Cilastastin
- UNII-141A6AMN38
- Cilastatin (Standard)
- CILASTATIN [MI]
- CILASTATIN [VANDF]
- CILASTATIN [WHO-DD]
Reported adverse events
- Headache
- Nausea
- Rash
- Seizure
- Vomiting
- Agitation
- Cyanosis
- Dizziness
- Dyskinesia
- Erythema
- Flushing
- Glossitis
Look up CILASTATIN in the interactive SynDRA portal →